Bio-Techne/$TECH

13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX

About Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Ticker

$TECH
Primary listing

Industry

Life Sciences Tools & Services

Employees

3,100

ISIN

US09073M1045

Bio-Techne Metrics

BasicAdvanced
$7.9B
60.40
$0.83
1.46
$0.32
0.64%

What the Analysts think about Bio-Techne

Analyst ratings (Buy, Hold, Sell) for Bio-Techne stock.

Bulls say / Bears say

Bio-Techne's GMP protein business has experienced significant growth, expanding from less than $5 million to over $60 million in annualized revenue within five years, with a 40% growth rate over the past year. This positions the company favorably in the rapidly growing cell and gene therapy market. (Investing.com)
The company reported a 7% increase in sales within its Protein Sciences unit, reaching $211.6 million in Q2 2025, indicating strong demand for its products used in research, diagnostics, and the development of cell and gene therapies. (TradingView News)
Bio-Techne has announced a new share buyback program of up to $500 million, reflecting confidence in its financial position and commitment to returning value to shareholders. (TradingView News)
Bio-Techne's Q4 2024 organic revenue increased by only 1%, indicating potential challenges in achieving significant growth amidst a competitive market. (Seeking Alpha)
The company missed revenue estimates in Q4 2024, with reported revenue of $306.1 million falling short by $244,370, suggesting potential difficulties in meeting market expectations. (Seeking Alpha)
Citigroup has reduced Bio-Techne's price target to $70.00, reflecting concerns about the company's future growth prospects and market performance. (Techdows News)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

Bio-Techne Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Bio-Techne Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TECH

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs